161 related articles for article (PubMed ID: 32458743)
21. Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.
Tremblay G; McElroy HJ; Westley T; Meier G; Misurski D; Guo M
PLoS One; 2019; 14(3):e0212899. PubMed ID: 30835737
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal SK; Puente J; Heng DYC; Glen H; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Ciuleanu T; Lee JL; Sunela K; O'Hara K; Binder TA; Peng L; Smith AD; Rha SY
Eur Urol; 2022 Sep; 82(3):283-292. PubMed ID: 35210132
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly A; Larkin J
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
25. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
26. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
[TBL] [Abstract][Full Text] [Related]
27. FDA Approves Drug Combo for Kidney Cancer.
Cancer Discov; 2016 Jul; 6(7):687-8. PubMed ID: 27267515
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib shows promise.
Stone L
Nat Rev Urol; 2015 Dec; 12(12):654. PubMed ID: 26526757
[No Abstract] [Full Text] [Related]
29. Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting.
Vogelzang NJ; Monnette AM; Wang Y; Wan Y; Xie Y; Robert NJ; Tannir NM
Clin Genitourin Cancer; 2021 Dec; 19(6):531-539. PubMed ID: 34112611
[TBL] [Abstract][Full Text] [Related]
30. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
31. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
32. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
Ged Y; Lee CH
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
[TBL] [Abstract][Full Text] [Related]
36. Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
Haas NB; Appleman LJ; Stein M; Redlinger M; Wilks M; Xu X; Onorati A; Kalavacharla A; Kim T; Zhen CJ; Kadri S; Segal JP; Gimotty PA; Davis LE; Amaravadi RK
Clin Cancer Res; 2019 Apr; 25(7):2080-2087. PubMed ID: 30635337
[TBL] [Abstract][Full Text] [Related]
37. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
38. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
39. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
40. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]